Perspective Therapeutics (CATX) Stock Statistics & Valuation Metrics

Perspective Therapeutics has a market cap or net worth of $142.18M. The enterprise value is $2.59M.

Perspective Therapeutics has 74,051,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Perspective Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Perspective Therapeutics is -2.31. Perspective Therapeutics’s PEG ratio is >-0.01.

In the last 12 months, Perspective Therapeutics had revenue of 1.43M and earned -46.51M in profits. Earnings per share was -1.40.

In the last 12 months, operating cash flow was -696.00K and capital expenditures -39.89M, giving a free cash flow of -40.59M billion.

Perspective Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Perspective Therapeutics upcoming earnings date is May 14, 2025, TBA Not Confirmed.

Perspective Therapeutics as a current ratio of 1.07, with Debt / Equity ratio of 1.30%

In the past 12 months, Perspective Therapeutics has paid -2.65M in taxes.

Perspective Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Perspective Therapeutics has $267.85M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$263.58M billion.

Gross margin is 100.00%, with operating margin of -2855.02%, and net profit margin of -3243.24%.

The average price target for Perspective Therapeutics is $14.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy